Literature DB >> 9626044

Bcl-2 and c-Myc, but not bax and p53, are expressed during human medullary thyroid tumorigenesis.

D G Wang1, W H Liu, C F Johnston, J M Sloan, K D Buchanan.   

Abstract

Medullary thyroid carcinoma (MTC) is a tumor of parafollicular cells of the thyroid gland. It has served as a useful experimental model for the study of tumor proliferation and differentiation. Although recent studies have identified the gene involved in familial forms of MTC, little is known about the molecular pathogenesis of the sporadic variants of this tumor. It has become increasingly clear that deregulation of programmed cell death is a critical component in multistep tumorigenesis. The present investigation was undertaken to determine whether similar molecular events occur in human MTC. Eighteen MTCs from 18 patients (including 12 sporadic and six familial cases and one metastatic lymph gland) and a MTC cell line (TT cells) were used in this study for detecting the expression of apoptosis-regulatory genes bcl-2, bax, c-myc, and p53. Immunohistochemical results showed that all MTC tumor samples displayed Bcl-2 and c-Myc immunoreactivity, whereas only 4 and 2 tumors showed a minority of cells positive for Bax and p53, respectively. Western and Northern blotting showed high levels of 26-kd Bcl-2 protein and bcl-2 transcript. The co-expression of Bcl-2 and c-Myc was also detected in the TT cells by indirect fluorescence immunohistochemistry and Western blotting. Moreover, Bcl-2 immunoreactivity was also found in C-cell hyperplasia from familial patients indicating that expression of this oncogene may represent an early event in the pathogenesis of MTC. The present study suggests that deregulation of programmed cell death may be a critical component in multistep tumorigenesis of MTC and that the frequent expression of the Bcl-2 oncoprotein in these tumors may contribute to their pathogenesis. The genetic complementation of simultaneously deregulated bcl-2 and c-myc may be implicated in the multistep tumorigenesis of human MTC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9626044      PMCID: PMC1858438     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  53 in total

Review 1.  Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease.

Authors:  C Eng
Journal:  N Engl J Med       Date:  1996-09-26       Impact factor: 91.245

2.  Detection of medullary thyroid cancer by calcitonin assay in families.

Authors:  C E Jackson; A H Tashjian; M A Block
Journal:  Ann Intern Med       Date:  1973-06       Impact factor: 25.391

Review 3.  The molecular genetics of cancer.

Authors:  J M Bishop
Journal:  Science       Date:  1987-01-16       Impact factor: 47.728

Review 4.  Cell division versus cell death: a functional model of multistep neoplasia.

Authors:  T J McDonnell
Journal:  Mol Carcinog       Date:  1993       Impact factor: 4.784

Review 5.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

6.  Expression of bcl-2 oncoprotein in pituitary tumours: comparison with c-myc.

Authors:  D G Wang; C F Johnston; A B Atkinson; A P Heaney; M Mirakhur; K D Buchanan
Journal:  J Clin Pathol       Date:  1996-10       Impact factor: 3.411

7.  Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism.

Authors:  K Yoshimoto; H Iwahana; A Fukuda; T Sano; S Saito; M Itakura
Journal:  Cancer Res       Date:  1992-09-15       Impact factor: 12.701

8.  Myc-mediated apoptosis is blocked by ectopic expression of Bcl-2.

Authors:  A J Wagner; M B Small; N Hay
Journal:  Mol Cell Biol       Date:  1993-04       Impact factor: 4.272

9.  Apoptosis and proliferation in thyroid carcinoma: correlation with bcl-2 and p53 protein expression.

Authors:  F Basolo; L Pollina; G Fontanini; L Fiore; F Pacini; A Baldanzi
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Inactivation of the p53 gene is not required for tumorigenesis of medullary thyroid carcinoma or pheochromocytoma.

Authors:  I Yana; T Nakamura; E Shin; K Karakawa; H Kurahashi; Y Kurita; T Kobayashi; T Mori; I Nishisho; S Takai
Journal:  Jpn J Cancer Res       Date:  1992-11
View more
  6 in total

1.  Expression of p63 and Bcl-2 in Malignant Thyroid Tumors and their Correlation with other Diagnostic Immunocytochemical Markers.

Authors:  Ashumi Gupta; Shyama Jain; Nita Khurana; Arun Kumar Kakar
Journal:  J Clin Diagn Res       Date:  2016-07-01

2.  Bcl-2 and p53 expression in insular and in well-differentiated thyroid carcinomas with an insular pattern.

Authors:  H E Peştereli; M Oğüş; N Oren; G Karpuzoğlu; T Kerpuzoğlu
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

3.  Expression of Bcl-2 and amplification of c-myc are frequent in basaloid squamous cell carcinomas of the esophagus.

Authors:  M Sarbia; C Loberg; M Wolter; J Arjumand; H Heep; G Reifenberger; H E Gabbert
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

4.  High resolution array-comparative genomic hybridization profiling reveals deoxyribonucleic acid copy number alterations associated with medullary thyroid carcinoma.

Authors:  Lei Ye; Libero Santarpia; Gilbert J Cote; Adel K El-Naggar; Robert F Gagel
Journal:  J Clin Endocrinol Metab       Date:  2008-09-02       Impact factor: 5.958

5.  New prognostic scales LAST-1 and LAST-2: supporting prediction and staging of thyroid cancer.

Authors:  Andrzej J Lachinski; Tomasz Stefaniak; Jarek Kobiela; Saxon Connor; Zbigniew Gruca; Zbigniew Sledzinski
Journal:  World J Surg       Date:  2006-03       Impact factor: 3.352

6.  Expression of glutamine metabolism-related proteins in thyroid cancer.

Authors:  Hye Min Kim; Yu Kyung Lee; Ja Seung Koo
Journal:  Oncotarget       Date:  2016-08-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.